Advice Pool - Real Estate

With house prices to rental income ratios deteriorating, suggesting de

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

clining attractiveness of residential properties as investment vehicle

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

, according to an article in Intellectual Property magazine.

Investor

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

activity plays an important role in the property market, especially o

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ce price increases start to accelerate and even more so when prices st

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

rt to fall. Says the Standard Bank: “Generally, investors are more lik

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ely than home owners to sell their property when they expect (or see)

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

fall in those prices. The simultaneous sell-off by investors to escap

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

e or limit capital losses aggravates the decline in property prices.

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

large presence of investors therefore gives the property market more

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

omentum and fuels the trend in house prices in either direction.

The

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ever-present danger in the investment market – residential and commerc

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

al – is lack of occupancy. This coupled with downward pressure on rent

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

al is beginning to squeeze the residential market – especially in area

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

where speculation became almost frenzied, such as the Western Cape. T

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

is applies particularly to the flat market, other than the Cape Town C

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

BD units and in suburbs around a hub, such as Century City. Interesti

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

gly, developers continue to build residential property and investment

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

buyers are still plentiful. This could change however if there is an u

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ward move in the interest rate as investors would be first to sell off

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/135599/advicepool-Is-the-Buy-to-Let-Market-Slowing-Down.html">Is the Buy to Let Market Slowing Down?</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/135599/advicepool-Is-the-Buy-to-Let-Market-Slowing-Down.html]Is the Buy to Let Market Slowing Down?[/url]

Increase your profit potential by identifying – and avoiding – these 11 marketing mistakes. MONSTROUS Marketing Mistake Number 1: Sinking a Fortune Into an Unproven Product Is your busine...

Fen-Phen: A Lawyer's Perspective... Fen-phen, a diet drug consisting of fenfluramine and phentermine, had been considered safe for many years until the FDA requested its removal from store shelves in 1997. Rising reports of heart valve disease and pulmonary hypertension caused the FDA to take the action against Fen-phen, particularly after echocardiograms of women who had ingested the drug indicated a 30% rate of heart valve abnormality, even though no other symptoms had been reported. Fen-phen has also been pinpointed as the drug responsible for causing dozens of cases of a rare valvular disease in women, as reported by the Mayo Clinic in July, 1997. Identification of this condition caused doctors to begin to warn their patients of the dangerous risks and conditions that could occur as a result of using Fen-phen.

Tags

Links

Advice Pool - Is the Buy to Let Market Slowing Down?

Related Articles: